Cardiac Science Strengthens Senior Management Team With Key Appointments.Business Editors & Health/Medical Writers BIOWIRE2K IRVINE, Calif.--(BW HealthWire)--April 16, 2001 Names New Chief Financial Officer, Chief Product Development Officer and Senior Vice President Operations Cardiac Science, Inc., (Nasdaq:DFIB) announced today that it has added further depth to its management team with the addition of two new senior executives. Roderick de Greef was appointed Executive Vice President and Chief Financial Officer ("CFO See Chief Financial Officer. ") and Guy Sohie, Ph.D. was appointed Senior Vice President -- Operations. In addition, Prabodh Mathur was promoted to Chief Product Development Officer. "Cardiac Science is in the midst Adv. 1. in the midst - the middle or central part or point; "in the midst of the forest"; "could he walk out in the midst of his piece?" midmost of a transformation from an early stage development company to a global entity focused on the rapid development and introduction of new cardiac-related medical products. Cardiac runs a world-class operation and is gaining critical mass through strategic acquisitions," said Raymond W. Cohen cohen or kohen (Hebrew: “priest”) Jewish priest descended from Zadok (a descendant of Aaron), priest at the First Temple of Jerusalem. The biblical priesthood was hereditary and male. , President and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. of Cardiac Science. "Mr. de Greef, Dr. Sohie and Mr. Mathur have distinguished themselves throughout their careers as dynamic leaders who have produced exceptional and measurable results. The addition of these individuals strengthens our management team and their experience will be invaluable as we integrate our recent acquisitions and execute our business plan." As Executive Vice President and CFO, Mr. Roderick de Greef will assume responsibility for the financial management of Cardiac Science and will oversee investor relations Investor relations The process by which the corporation communicates with its investors. . Since 1995, Mr. de Greef has provided corporate finance advisory services advisory services advisory services provided to the public, in their capacity as owners and managers of animals, are an important part of veterinary science. They may be provided by government bureaux, by commercial companies who deal in pharmaceuticals or animals or animal to a number of early stage companies. He has served as an advisor to Cardiac Science's Board of Directors since early 1997 and has been instrumental in introducing the company to some of its recent investors as well as advising the company on its merger and acquisition activity. Mr. de Greef holds a B.S. in Economics and International Relations from the San Francisco State University • • [ and an M.B.A. from the University of Oregon The University of Oregon is a public university located in Eugene, Oregon. The university was founded in 1876, graduating its first class two years later. The University of Oregon is one of 60 members of the Association of American Universities. . Guy Sohie, Ph.D., assumes the role of Senior Vice President of Operations and will be responsible for manufacturing and global operations at Cardiac Science. Previously, Dr. Sohie served as principal consultant to Global Insite, advising companies on operational issues and product development. For a number of years, Dr. Sohie was a senior manager at General Electric ("GE") Medical Systems (Europe), responsible for the introduction and development of new imaging systems for GE's global x-ray business. Prior to joining GE, Dr. Sohie was an engineer with Motorola's digital signal processor A digital signal processor (DSP) is a specialized microprocessor designed specifically for digital signal processing, generally in real-time computing. Characteristics of typical Digital Signal Processors
Prabodh Mathur was instrumental in the formation of Cardiac Science in 1991 and led the development of the company's core technology for six years. Mr. Mathur rejoined the company in May 2000 as Vice President of Research and Development. He was recently promoted to the newly created position of Chief Product Development Officer. In his new role, Mr. Mathur will oversee new product development using Cardiac Science's proprietary technology. Previously, Mr. Mathur was vice president of engineering at Medstone International Inc., a manufacturer of shockwave lithotripters, used in the treatment of kidney stones Kidney Stones Definition Kidney stones are solid accumulations of material that form in the tubal system of the kidney. Kidney stones cause problems when they block the flow of urine through or out of the kidney. . Mr. Mathur holds a Masters degree in Engineering from the University of Missouri and a B.S. in Mechanical Engineering from the Indian Institute of Technology. About Cardiac Science Cardiac Science develops and markets life-saving external cardiac defibrillator defibrillator, device that delivers an electrical shock to the heart in order to stop certain forms of rapid heart rhythm disturbances (arrhythmias). The shock changes a fibrillation to an organized rhythm or changes a very rapid and ineffective cardiac rhythm to a devices and proprietary software that monitors a patient's cardiac activity, instantly detects the onset of a life-threatening heart rhythm and automatically delivers defibrillation Defibrillation Definition Defibrillation is a process in which an electronic device sends an electric shock to the heart to stop an extremely rapid, irregular heartbeat, and restore the normal heart rhythm. without human intervention. The company's proprietary technology has multiple applications, including use in external and wearable defibrillators and with standard patient monitors widely used in hospitals throughout the world. The growth of the company's installed base of devices provides a potential recurring revenue stream from the sale of proprietary disposable defibrillator electrodes. Cardiac Science began marketing its first commercial product, the Powerheart(R) in the United States in early 2000. For more information, visit www.cardiacscience.com. This news release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. Such forward looking statements include, but are not limited to: the lifesaving potential of Cardiac Science's technology, accelerate the rapid development of the Company's technology, generate significant recurring revenue, potentially save thousands of lives, and develop new products using proprietary technology. Cardiac Science cautions that these statements are subject to substantial risks and uncertainties and are qualified by important factors that could cause actual results to differ materially from those reflected by the forwarding-looking statements and should not be relied upon by investors when making an investment decision. Information on these and other factors is detailed in the Company's Form 10-K Form 10-K A report required by the SEC from exchange-listed companies that provides for annual disclosure of certain financial information. Form 10-K See 10-K. for the year ending December 31, 2000 and other documents filed with the Securities and Exchange Commission. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion